Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

December 3, 2007

Big 3 Wholesalers Ramp Up Sourcing from India

Analysis of: US big 3 look for new Indian drug suppliers | www.business-standard.com
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Analysis By:
Adam Fein, PhD, Founder & PresidentAdam Fein, PhD
Founder & President, Pembroke Consulting Inc
Implications: The Indian newspaper Business Standard has a fascinating article on the Big 3 wholesalers' search for Indian suppliers. Wholesalers seem to be moving closer to production to source generics, possibly even bypassing the generic manufacturers for certain products.

Analysis:

The article quotes "informed industry sources" that at least ten tier-II and tier-III Indian pharmaceutical companies with plants in Mumbai, Ahmedabad and Hyderabad are on the radar of AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK).

"Over the past few months, McKesson and Cardinal Health have sent executives to India to assess the capabilities of these companies, the sources said."

In a previous posting, I speculated that wholesalers will be moving closer to production to source generics, possibly even bypassing the generic manufacturers for certain products.  (See Cardinal Health Gets Closer to Alliance Boots – Council Site)  The Big 3 are following in the footsteps of wholesalers in other industries and aggressively ramping up their private label programs.

What does this mean?

  • More pressure on generic manufacturers -- and more consolidation to come.
  • Lower acquisition costs for generic drugs -- and lower Average Manufacturer Price (AMP) calculations
  • More rapid generic penetration for drugs going off patent.
  • Less attention to brands by distribution as the profits from generics grow faster (Wholesalers currently generate more gross profit dollars from generics than brands.)

The Big 6 chain and mail-order pharmacies -- CVS Corp with CareMark (CVS), Express Scripts (ESRX), Medco (MHS), Rite-Aid (RAD), Walgreens (WAG), and Wal-Mart (WMT) -- are the other major customers of generic manufacturers. They currently bypass wholesalers to buy generics except for fill-in and some minimal direct store delivery (DSD).

But as far as I know, the Big 6 are not being as aggressive in looking at India or China. If the Big 3 could source generics cheaply enough, then wholesalers could pick up major generic business from their largest customers.



Report a Concern

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T17:45:17.163